The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Paul E Gray¹, Yvonne Belessis²

Affiliations

¹ Dept. of Immunology and Infectious Diseases, Sydney Children's Hospital, Sydney, Australia; School of Women's and Children's Health, University of New South Wales, Sydney, Australia. Electronic address: paul.gray1@health.nsw.gov.au.
² School of Women's and Children's Health, University of New South Wales, Sydney, Australia; Dept. of Respiratory Medicine, Sydney Children's Hospital, Sydney, Australia.

PMID: 32251726
PMCID: PMC7129235
DOI: 10.1016/j.phrs.2020.104776

Comment

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Paul E Gray et al. Pharmacol Res. 2020 Jun.

. 2020 Jun:156:104776.

doi: 10.1016/j.phrs.2020.104776. Epub 2020 Apr 3.

Authors

Paul E Gray¹, Yvonne Belessis²

Affiliations

¹ Dept. of Immunology and Infectious Diseases, Sydney Children's Hospital, Sydney, Australia; School of Women's and Children's Health, University of New South Wales, Sydney, Australia. Electronic address: paul.gray1@health.nsw.gov.au.
² School of Women's and Children's Health, University of New South Wales, Sydney, Australia; Dept. of Respiratory Medicine, Sydney Children's Hospital, Sydney, Australia.

PMID: 32251726
PMCID: PMC7129235
DOI: 10.1016/j.phrs.2020.104776

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest There are no conflicts to declare.

Comment in

Reply to "The use of traditional Chinese medicines to treat SARS-CoV-2 may cause more harm than good".
Zhang AH, Ren JL, Wang XJ. Zhang AH, et al. Pharmacol Res. 2020 Jul;157:104775. doi: 10.1016/j.phrs.2020.104775. Epub 2020 Apr 3. Pharmacol Res. 2020. PMID: 32251725 Free PMC article. No abstract available.

Comment on

Traditional Chinese medicine for COVID-19 treatment.
Ren JL, Zhang AH, Wang XJ. Ren JL, et al. Pharmacol Res. 2020 May;155:104743. doi: 10.1016/j.phrs.2020.104743. Epub 2020 Mar 4. Pharmacol Res. 2020. PMID: 32145402 Free PMC article. No abstract available.

Cited by

Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Faheem, Kumar BK, Sekhar KVGC, Kunjiappan S, Jamalis J, Balaña-Fouce R, Tekwani BL, Sankaranarayanan M. Faheem, et al. Bioorg Chem. 2020 Nov;104:104269. doi: 10.1016/j.bioorg.2020.104269. Epub 2020 Sep 8. Bioorg Chem. 2020. PMID: 32947136 Free PMC article. Review.
Databases for facilitating mechanistic investigations of traditional Chinese medicines against COVID-19.
Jiang S, Cui Q, Ni B, Chen Y, Tan Y, Chen W, Chen YZ. Jiang S, et al. Pharmacol Res. 2020 Sep;159:104989. doi: 10.1016/j.phrs.2020.104989. Epub 2020 Jun 2. Pharmacol Res. 2020. PMID: 32502638 Free PMC article. No abstract available.
Chinese Medicine Meets Conventional Medicine in Targeting COVID-19 Pathophysiology, Complications and Comorbidities.
Wang SS, Zeng X, Wang YL, Dongzhi Z, Zhao YF, Chen YZ. Wang SS, et al. Chin J Integr Med. 2022 Jul;28(7):627-635. doi: 10.1007/s11655-022-3573-0. Epub 2022 May 18. Chin J Integr Med. 2022. PMID: 35583580 Free PMC article.
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Slimano F, Baudouin A, Zerbit J, Toulemonde-Deldicque A, Thomas-Schoemann A, Chevrier R, Daouphars M, Madelaine I, Pourroy B, Tournamille JF, Astier A, Ranchon F, Cazin JL, Bardin C, Rioufol C. Slimano F, et al. Cancer Treat Rev. 2020 Aug;88:102063. doi: 10.1016/j.ctrv.2020.102063. Epub 2020 Jun 23. Cancer Treat Rev. 2020. PMID: 32623296 Free PMC article. Review.
Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.
Hanna R, Dalvi S, Sălăgean T, Pop ID, Bordea IR, Benedicenti S. Hanna R, et al. J Inflamm Res. 2021 Jan 7;14:13-56. doi: 10.2147/JIR.S282213. eCollection 2021. J Inflamm Res. 2021. PMID: 33447071 Free PMC article. Review.

See all "Cited by" articles

References

1. Ren J.L., Zhang A.H., Wang X.J. Traditional Chinese medicine for COVID-19 treatment. Pharmacol. Res. 2020:104743. - PMC - PubMed
1. Jin Y.H., Cai L., Cheng Z.S. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) Mil. Med. Res. 2020;7:4. - PMC - PubMed
1. Enomoto Y.M., Nakamura Y.M.P., Enomoto N.M.P., Fujisawa T.M.P., Inui N.M.P., Suda T. Japanese herbal medicine-induced pneumonitis: a review of 73 patients. Respir. Investig. 2017;55:138–144. - PubMed
1. Shimada Y., Fujimoto M., Nogami T., Watari H. Adverse events associated with ethical kampo formulations: analysis of the domestic adverse-event data reports of the ministry of health, labor, and welfare in Japan. Evid. Complement. Alternat. Med. 2019;2019 - PMC - PubMed
1. Sakamoto O., Ichikado K., Kohrogi H., Suga M. Clinical and CT characteristics of Chinese medicine-induced acute respiratory distress syndrome. Respirology. 2003;8:344–350. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Affiliations

The use of Traditional Chinese Medicines to treat SARS-CoV-2 may cause more harm than good

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Miscellaneous